The Evolving Landscape of HIV Prevention and Diagnosis

Size: px
Start display at page:

Download "The Evolving Landscape of HIV Prevention and Diagnosis"

Transcription

1 The Evolving Landscape of HIV Prevention and Diagnosis Jenny R. McFarlane Texas Department of State Health Services HIV/STD/TB/Viral Hepatitis Unit

2 Is it okay if we just talk?

3 NHAS: A Call to ACT Reduce New HIV Infections Increase Access to Care and Improve Health Outcomes Reduce HIV-related Health Disparities and Health Inequities.

4 Newly Diagnosed HIV, PLWH, And Deaths TEXAS 6,000 82,745 People Living with HIV 80,000 5,000 4,486 70,000 New dx and Deaths 4,000 3,000 2,000 New Diagnoses 60,000 50,000 40,000 30,000 People Living with HIV 1,000 Deaths 1,324 20,000 10,

5 Texas HIV Treatment Cascade, , % 100% 70,000 60,000 77% 69% 80% 50,000 59% 60% 40,000 82,745 30,000 20,000 63,706 57,074 48,632 40% 20% 10,000 0 Individuals Living with HIV at end of 2015 At Least One Visit/Lab Retained In Care Achieved Viral Suppression 0%

6 The Bars!

7 Percentage of People Living with HIV and Percentage of HIV Transmissions at Each Stage of the Care Continuum, United States and Puerto Rico, Frieden TR et al. N Engl J Med 2015;373:

8 HIV Transmissions At Each Stage Of The Care Continuum Texas % 5% 5% 5% 9% 55% 6% 32% 30% 14% Texans with HIV Transmissions People with undx infec:ons Persons dx but not in care In care no ART On ARV but not suppressed Viral suppression

9 What does this have to do with Testing Technology? Diagnosis is the first step. Do I know how to test? Am I using the best technology to detect early infection? Why is it important to detect early?

10

11

12 Serologic Assay Generations 1 st generation immunoassays (IA) Detects HIV antibody (Ab) IgG using viral lysates as the antigens (Ag) Western BLOT 1 st gen assay

13 2 nd Gen CLIA-Waived Point-of-Care Rapid HIV Tests Detects HIV IgG Antibody The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. Clearview Complete ChemBio Stat Pak OraQuick Advance

14 3rd Generation Detects HIV 1/2 IgG and IgM Antibodies Siemans ADVIA Centaur - LAB Ortho VITROS Sei/ECIQ - LAB Ortho GS 1/2 +O - LAB Time to results minutes Insti Unigold The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

15 Antigen/Antibody Combo Detects HIV 1 p24 Antigen and HIV 1/2 IgG and IgM Antibodies The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

16

17 Bio Plex 2200 Detects HIV 1/2 antibodies and p24 Antigen Load and run if no detection Negative Detection - runs again and will isolate what it found. Will tell us HIV 1, HIV 2, p24 antigen The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

18 If BioPlex Reactive what s Next?

19 HIV 1/2 Antibody Differentiation HIV 1/2 Geenius HIV 1/2 Multi Spot The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

20 Nucleic Acid The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

21 The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

22 Determine Combo Rapid HIV 1/2 Ag-Ab Test Alere 4 th generation technology The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. Control Antigen Antibody The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

23 Determine HIV 1/2 Ag/Ab Early Infection Plasma Ag not detected most Acutes (Laperche, Rosenberg, Kilembe, Duong, Conway, Faraoni) Detects infection earlier than IgM-sensitive assays, not as early as Ag/Ab assays (Masciotra, JCV) Detected 40 54% early infections (Delaney, Masciotra, Dx conference) Whole Blood 0% Ag sensitivity, Acutes (Lewis, AIDS)

24 NATs on the Horizon The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

25 Acute Viral Infection Malaise/fatigue Fever/chills/night sweats Weight loss, loss of appetite Sore throat Nausea/vomiting/diarrhea Swollen lymph nodes Aching muscles or joints Rash Rarely headache, neurologic symptoms

26 Clinical Syndrome of Acute HIV 40% 90% develop symptoms of Acute HIV à 50% 90% w/ symptoms seek medical care Of those diagnosed with Acute HIV à 50% of patients were seen at least 3 times before diagnosis Kahn et al, NEJM 1998, Weintrob et al, Arch Int Med 2003

27

28 Prediction of the efficiency of HIV transmission according to HIV burden in the genital tract. Cohen M S, and Pilcher C D J Infect Dis. 2005;191: by the Infectious Diseases Society of America

29 Acute HIV: Partner Notification Persons with acute HIV infection named 2.5 times as many sex partners 1.9 times as many partners newly diagnosed with HIV as did persons with new diagnosis of established HIV infection -Moore et al, JAIDS 2009

30 The Bars! Very T e s ti Linkage! Harm Reduction n g P ar t n e r T e s ti A R TA STI screen & tx Maintenance P r E P n g S P r E P

31

32 Transitions and Change Benefits and Challenges Please Ponder How can this improve your services, the quality of care your patients receive and the overall health of your community?

33 Case Studies 17 yo male rapid test INSTI prelim + Referred to clinic for follow up testing No show No blood specimen to NAAT test 26 yo male screening Ag/Ab Combo + Geenius negative NAAT +, VL 260K copies. 30 yo pregnant woman 3 rd gen + Geenius Indeterminate NAAT +

34 Transition to Best Practices Current Test Technology Used Staff training Technology Specimen Collection Messaging/Counseling Administration Link to Care Public Health Follow up

35 Specimen Collection HIV-1/2 Ag/Ab Combo No more than 5 days cold. Gold top, :ger top, spin before submit. NO DRY BLOOD SPOT. Reac:ve samples run in duplicate. Geenius HIV 1/2 Differen:a:on Reflex from reac:ve Ag/Ab Combo. 25 minute average run :me. Read immediately once test completed.

36 Why does this matter? Early id of infection has individual and positive public health benefits Laboratory testing offers the best potential for early diagnosis No test is perfect limitations of tests are important to understand relay to the client. New technology available now and on the horizon will likely change the algorithm

37 Where do I fit in? Testing Education Promotion Referral AND Follow-up And Follow-up Support YOU MATTER!

38 Laboratory Testing for the Diagnosis of HIV Infection Updated Recommendations HIVtestingAlgorithmRecommendation- Final.pdf

39

40 Resources To order materials from the DSHS Warehouse: Diagnostic-Testing-Algorithm.aspx option=com_content&task=view&id=774&itemid=92 S270.full.pdf+html

41 Acknowledgements Michelle Owen, Ph.D- CDC Bernard Branson, MD Ann Robbins, Ph.D DSHS Margaret Vaaler, Ph.D DSHS Shelley Lucas, MPH - DSHS Isabel Clark, MS DSHS

42 Jenny R. McFarlane Prevention Manager Texas DSHS HIV/STD/TB Viral Hepatitis Unit (512)

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd

More information

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection

More information

The Latest in HIV Tests: What Do the Results Mean?

The Latest in HIV Tests: What Do the Results Mean? The Latest in HIV Tests: What Do the Results Mean? Bernard M. Branson MD Principal Consultant, Scientific Affairs LLC Atlanta, Georgia Objectives At the end of this workshop, participants will be able

More information

HIV Testing Technology and the Latest Algorithm

HIV Testing Technology and the Latest Algorithm HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with

More information

1 st and 2 nd Generation EIA

1 st and 2 nd Generation EIA HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation

More information

Routine HIV Testing Community of Practice Session #2

Routine HIV Testing Community of Practice Session #2 Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing

More information

Point-of-care HIV testing

Point-of-care HIV testing Point-of-care HIV testing Joanne Stekler, MD MPH Associate Professor University of Washington December 5, 2016 Disclaimer: The findings and conclusions in this presentation are those of the author(s) and

More information

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*

Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages

More information

New HIV Tests and Algorithm: A change we can believe in

New HIV Tests and Algorithm: A change we can believe in New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be

More information

Overview of HIV Testing Practices and Technology

Overview of HIV Testing Practices and Technology Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease

More information

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What

More information

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016 New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new

More information

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention

Evolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like

More information

2018 HIV and HCV Diagnostic Testing Survey

2018 HIV and HCV Diagnostic Testing Survey 2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will

More information

A Summary of Clinical Evidence

A Summary of Clinical Evidence A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table

More information

Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program

Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV Testing Joanne Stekler, MD, MPH Assistant Professor of Medicine Deputy Director, Public Health Seattle & King County HIV/STD Program Presentation prepared

More information

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging

More information

High Sensitivity HIV Testing and Translational Science around PrEP

High Sensitivity HIV Testing and Translational Science around PrEP High Sensitivity HIV Testing and Translational Science around PrEP Joanne Stekler, MD MPH Associate Professor, Department of Medicine University of Washington Inter-Center for AIDS Research Antiretrovirals

More information

Diagnostic Tests for HIV

Diagnostic Tests for HIV Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,

More information

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC) HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC

More information

HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES

HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES ISSUES IN BRIEF: MEMBER SURVEY OF HIV ASSAY USE ASSOCIATION OF PUBLIC HEALTH LABORATORIES MARCH 2010 HIV: 2009 DIAGNOSTIC SURVEY FACING NEW CHALLENGES Twenty years ago, the Association of Public Health

More information

INTEGRATING HIV AND HCV TESTING

INTEGRATING HIV AND HCV TESTING INTEGRATING AND HCV TESTING OVERVIEW Increasingly health departments (HDs) are seeking new strategies to improve the productivity and yield of testing and linkage programs, expand availability of and access

More information

Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection

Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection Failure of the Alere Determine 4th Generation HIV POC test to Detect an Acute Case of HIV-1 Infection Carol Loring, MS Rachel Gridley Fengxiang Gao, MD, MPH NH Public Health Laboratories Concord, NH Conflicts

More information

Adventures in Discordance- HIV Testing

Adventures in Discordance- HIV Testing Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody

More information

HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D.

HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D. HIV/HCV Screening in 2015: Where Are We Now? Bernard M. Branson, M.D. Disclosures Dr. Branson has no financial interests to disclose. Terminology Diagnostic testing: performing a test based on clinical

More information

Diagnosis and Management of Acute HIV

Diagnosis and Management of Acute HIV Diagnosis and Management of Acute HIV A New HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV, this committee

More information

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes

More information

Arizona State Office of Rural Health Webinar Series

Arizona State Office of Rural Health Webinar Series Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording

More information

NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM)

NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM) NEW CHALLENGES FOR ACCURATE HIV-1 DIAGNOSIS ALL BELGIAN AIDS REFERENCE LABORATORIES KAROLIEN STOFFELS (ARL VUB STP) & FIEN VANROYE (ARL ITM) 30 NOVEMBER 2018, BRUGGE 0 NEW CHALLENGES FOR ACCURATE HIV-1

More information

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 Shipping and Submission Instructions Thank you for participating as a submitting

More information

An Evaluation of Qualitative HIV-2 RNA Referral Testing

An Evaluation of Qualitative HIV-2 RNA Referral Testing An Evaluation of Qualitative HIV-2 RNA Referral Testing Linda M. Styer, Anne Gaynor, Laura Wesolowski, Steve Ethridge and Monica M. Parker Wadsworth Center, NYSDOH; APHL; Division of HIV/AIDS Prevention,

More information

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental

More information

OR: Steps you can take in the clinic to prevent HIV infections

OR: Steps you can take in the clinic to prevent HIV infections Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute

More information

Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic

Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic algorithms KP Delaney, M Pentella, B Bennett, and K Landgraf for the CDC/APHL

More information

HIV Testing: What s New? Kenneth H. Mayer, MD

HIV Testing: What s New? Kenneth H. Mayer, MD HIV Testing: What s New? Kenneth H. Mayer, MD CART Symposium, Chennai, India April 28 th, 2018 thefenwayinstitute.org The Status Neutral Continuum HIV Testing RETAINED ON PrEP PRESCRIBED PrEP LINKED TO

More information

2017 HIV AND HCV DIAGNOSTICS SURVEY REPORT

2017 HIV AND HCV DIAGNOSTICS SURVEY REPORT 207 HIV AND HCV DIAGNOSTICS SURVEY REPORT MARCH 209 Table of Contents Background...3 Methods...3 Workforce...3 HIV Assay Utilization...4 Turnaround Time...6 Testing Volume and Specimen Types...7 Testing

More information

Clinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M.

Clinical Education Initiative TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING. Bernard M. Clinical Education Initiative Support@ceitraining.org TESTING FOR HIV AND HCV: WHAT S CURRENT AND WHAT S COMING Bernard M. Branson, MD 1/23/2018 Testing for HIV and HCV: What s Current and What s Coming

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.

More information

Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm

Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Ability to Identify Acute HIV Infections from Surveillance Data Varies by Diagnostic Testing Algorithm Laurie Linley, MPH; Anne H. Peruski, MPH, PhD; Richard M. Selik, MD; Kevin P. Delaney, MPH, PhD; Alexandra

More information

AdvaMedDx Value Assessment Framework in Practice

AdvaMedDx Value Assessment Framework in Practice AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody

More information

AccuSet HIV-1/2 Performance Panel

AccuSet HIV-1/2 Performance Panel OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple

More information

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection ===========ir ~~!!~~fk li=:='========= Nirav R. Shah, M.D., M.P.H. Commissioner May 16, 2013 HEALTH Sue Kelly Executive Deputy Commissioner Re: Interim Guidelines for Laboratories on the use of a new Diagnostic

More information

Rapidly Growing Molecular Clusters of HIV in Texas. Analise Monterosso, MPH Epidemiologist Molecular HIV Surveillance Coordinator

Rapidly Growing Molecular Clusters of HIV in Texas. Analise Monterosso, MPH Epidemiologist Molecular HIV Surveillance Coordinator Rapidly Growing Molecular Clusters of HIV in Texas Analise Monterosso, MPH Epidemiologist Molecular HIV Surveillance Coordinator Outline HIV in Texas HIV Drug Resistance testing (genotyping) in Texas Molecular

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV? Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection

More information

Unigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS

Unigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS Unigold Recombigen HIV 1/2 Training for HIV Testing Sites Updated: February 2018 Cicely Richard Office of HIV/AIDS Updated: February 2018 Cicely Richard Office of HIV/AIDS UNIGOLD RECOMBIGEN HIV 1/2 TRAINING

More information

Linkage to care and initiating ART after diagnosis with acute or established HIV infection in 8 US emergency departments

Linkage to care and initiating ART after diagnosis with acute or established HIV infection in 8 US emergency departments Linkage to care and initiating ART after diagnosis with acute or established HIV infection in 8 US emergency departments Thomas P. Giordano (Presenter), Baylor College of Medicine, Houston, TX Siavash

More information

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Disclosures None Objectives 1. Outline the CDC recommendations for HIV

More information

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World

SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our

More information

The Latest on HIV Testing. Dominika Seidman, MD MAS

The Latest on HIV Testing. Dominika Seidman, MD MAS The Latest on HIV Testing Dominika Seidman, MD MAS Disclosures none 2 Learning objectives At the conclusion of this session, participants should be able to Define the window periods for various HIV tests

More information

Rapid testing algorithm performance in a low prevalence environment: NJ

Rapid testing algorithm performance in a low prevalence environment: NJ Rapid testing algorithm performance in a low prevalence environment: NJ 2015-8 Alere Determine HIV-1/2 Ag/Ab Combo Trinity Biotech Uni-Gold HIV1/2 Recombigen Eugene G. Martin, PhD HIV Diagnostics Conference

More information

2006 HIV Diagnostics Survey

2006 HIV Diagnostics Survey Public Health Laboratory Issues in Brief: 2006 HIV Diagnostics Survey Association of Public Health Laboratories November 2007 Background Nearly 20 years ago, the Association of Public Health Laboratories

More information

Robert Wood Johnson Medical School NJ HIV: Status Update

Robert Wood Johnson Medical School NJ HIV: Status Update Robert Wood Johnson Medical School NJ HIV: Status Update Eugene G. Martin, Ph.D Professor of Pathology and Laboratory Medicine Co-Director, NJ HIV Rutgers, The State University of New Jersey 1. NJ HIV

More information

TAP HERE TO SEE THE PRODUCT

TAP HERE TO SEE THE PRODUCT TAP HERE TO SEE THE PRODUCT Make every testing opportunity count. Acute infection accounts for 5-20% of all cases of HIV infection among persons seeking testing.1 This acute phase of infection is associated

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Rapid HIV Antibody Testing Update

Rapid HIV Antibody Testing Update Rapid HIV Antibody Testing Update Devery Howerton, Ph.D. Division of Laboratory Systems Centers for Disease Control and Prevention CLIAC meeting, February 15, 2007 Purpose: Why Rapid HIV Testing? An example

More information

Modernization of North Carolina s HIV control measures

Modernization of North Carolina s HIV control measures Modernization of North Carolina s HIV control measures North Carolina Division of Public Health Victoria Mobley, MD MPH Evelyn Foust, MPH CPM Agenda Introduction Summary of scientific evidence used to

More information

CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING

CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING Institute of Medicine (2010) CAPACITY OF THE HEALTHCARE SYSTEM TO INCREASE PROVISION OF HIV TESTING Workshop on the Capacity of the Healthcare System to Identify and Provide Care for Individuals with HIV/AIDS

More information

Integrating HIV Screening Into

Integrating HIV Screening Into MaxiMizing Third ParTy reimbursement for hiv TesTing Integrating HIV Screening Into Title X Services IntroductIon HIV screening services are a core family planning service, and all individuals aged 13-64

More information

HIV Screening & Consent for Testing

HIV Screening & Consent for Testing 1. Algorithm for HIV Screening 2. Screening & Consent for HIV Testing a. Offering testing b. Counseling on HIV Risk Factors c. Pre-test Counseling d. Post-test Counseling 1. Positive Result 2. Preliminary

More information

Bruce D. Agins, MD MPH Medical Director, AIDS Institute Adherence 2017; Miami

Bruce D. Agins, MD MPH Medical Director, AIDS Institute Adherence 2017; Miami 1 1 Bruce D. Agins, MD MPH Medical Director, AIDS Institute Adherence 2017; Miami 3 Defining the End of AIDS Reduce new infections to 750 annually by the end of 2020 Three Point Plan 1. Identify all persons

More information

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town HOPE Follow-Up Algorithm: Unusual Cases Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town MTN-025 Testing Algorithm Screening/Enrollment MTN-025 Testing Algorithm

More information

Technical Bulletin No. 104b

Technical Bulletin No. 104b CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104b June 22, 2016 Update to Guidelines for Diagnosing HIV Infection CPAL s Testing Algorithm for Diagnostic HIV Testing HIV Geenius

More information

Shared Service Success

Shared Service Success Shared Service Success Six Years of HIV Nucleic Acid Testing for US Public Health Laboratories A Gaynor, M Parker, B Bennett, L. Wesolowski, S. Ethridge, T. Sullivan, S. Fordan, K. Wroblewski Conflict

More information

GOAL1 GOAL 2 GOAL 3 GOAL 4

GOAL1 GOAL 2 GOAL 3 GOAL 4 AIDS Education and Training Center s Response to the National HIV/AIDS Strategy (NHAS) and HIV Care Continuum: FINDINGS FROM FUNDING YEAR 1-15 The mission of the AIDS Education and Training Centers Program

More information

How are testing technologies used to diagnose HIV infection?

How are testing technologies used to diagnose HIV infection? HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original

More information

Comprehensive HIV/AIDS Resources and Linkages for Inmates (CHARLI) and Care Coordination (CC) Collaborative. Care Coordination

Comprehensive HIV/AIDS Resources and Linkages for Inmates (CHARLI) and Care Coordination (CC) Collaborative. Care Coordination Comprehensive HIV/AIDS Resources and Linkages for Inmates (CHARLI) and Care Coordination (CC) Collaborative CHARLI CHARLI Contract Monitor Susan Carr HIV Prevention Unit Virginia Department of Health Susan.Carr@vdh.virginia.gov

More information

100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010

100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010 Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories

More information

HIV Guideline Sakchai Dettrairat

HIV Guideline Sakchai Dettrairat HIV Guideline 2016 Sakchai Dettrairat Division of Clinical Immunology Department of Medical Technology Faculty of Associated Medical Sciences Chiang Mai University Appearance of HIV markers in early HIV

More information

The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013

The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 Christopher Bentsen, M.S.,RAC, FRAPS Bio-Rad Laboratories, Redmond,

More information

HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version

HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version 1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: ADULT HIV 900 (AIDS.gov 12/31/2015) HIV Lifelong HIV (human immunodeficiency virus) is a retrovirus

More information

Rubella rev Jan 2018

Rubella rev Jan 2018 rev Jan 2018 Infectious Agent virus (family Togaviridae; genus Rubivirus) BASIC EPIDEMIOLOGY Transmission is spread from person to person via direct or droplet contact shed from nasopharyngeal secretions

More information

M E D I C A L L A B O R A T O R Y

M E D I C A L L A B O R A T O R Y M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...

More information

Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model

Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model Regional program of the East Europe and Central Asia Union of PLWH within the framework of the Global Fund New Funding Model Background for the program development Problem areas Access to the whole HIV-care

More information

Cleveland Prevention Update. Zach Reau HIV Prevention Program Manager Ohio Department of Health

Cleveland Prevention Update. Zach Reau HIV Prevention Program Manager Ohio Department of Health Cleveland Prevention Update Zach Reau HIV Prevention Program Manager Ohio Department of Health May 21-22, 2018 ODH HIV PREVENTION PROGRAM 2018-2019 Overview Client Services Team Client Services Administrator-

More information

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance Kristen Mahle, MPH HIV Incidence & Case Surveillance Branch DHAP, NCHHSTP, CDC 2010 Diagnostics Conference March 24, 2010

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27

HIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Revised

More information

AccuSet Anti-HIV-1 Mixed Titer Performance Panel

AccuSet Anti-HIV-1 Mixed Titer Performance Panel PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test

More information

Program to control HIV/AIDS

Program to control HIV/AIDS 90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,

More information

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad Immunologic Methods in Diagnosis of HIV Infection M Parsania, Ph.D. Tehran Medical Sciences Branch, Islamic Azad University Retroviridae Retroviruses (family Retroviridae) id ) are enveloped, single stranded

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

M E D I C A L L A B O R A T O R Y

M E D I C A L L A B O R A T O R Y M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 7 Immunology 2017 MLE-M3 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...

More information

Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings

Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings Dennis Fleming, MA CDPH/Office of AIDS DHCS Statewide SUD Conference August 23, 2018 Anaheim, CA Agenda What s New in

More information

Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots

Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots Comparison of the Geenius HIV-1/2 Supplemental Assay and HIV-1 Western blot for HIV rapid test confirmation from dried blood spots Timothy J. Sullivan Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH

More information

AccuVert HIV-1 Seroconversion Panel PRB974 ( )

AccuVert HIV-1 Seroconversion Panel PRB974 ( ) PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers

More information

Kelly A. Curtis, M. Susan Kennedy, Kevin Delaney, Man Charurat, and S. Michele Owen

Kelly A. Curtis, M. Susan Kennedy, Kevin Delaney, Man Charurat, and S. Michele Owen Kelly A. Curtis, M. Susan Kennedy, Kevin Delaney, Man Charurat, and S. Michele Owen Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA Advantages: Obvious evolution

More information

Obstetrics and HIV An Update. Jennifer Van Horn MD University of Utah

Obstetrics and HIV An Update. Jennifer Van Horn MD University of Utah Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

Clinical Education Initiative THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE. Speaker: Antonia Urbina, MD

Clinical Education Initiative THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE. Speaker: Antonia Urbina, MD Clinical Education Initiative Support@ceitraining.org THE ROLE OF THE PRIMARY CARE CLINICIAN IN HIV CARE Speaker: Antonia Urbina, MD 2/1/2017 The Role of the Primary Care Clinician in HIV Care [video transcript]

More information

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin

More information

Module 3: Overview of HIV Testing Technologies

Module 3: Overview of HIV Testing Technologies Module 3: Overview of HIV Testing Technologies Purpose Pre-requisite Modules Module Time Learning Objectives To provide the participants with a basic knowledge of HIV testing and how HIV rapid test results

More information

Negative Hepatitis C Reporting and Linkage to Care Outreach

Negative Hepatitis C Reporting and Linkage to Care Outreach Negative Hepatitis C Reporting and Linkage to Care Outreach NASTAD 7 th National Hepatitis Technical Assistance Meeting November 28-30, 2017 Angelica Bocour, MPH Director of Viral Hepatitis Surveillance

More information

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed

Expression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single

More information

A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery

A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery A Case of False-Positive Test Results in a Pregnant Woman of Unknown HIV Status at Delivery Pascale Akl, MD, 1 Kenneth E. Blick, PhD 1* Lab Med Spring 2014;45:259-263 DOI: 10.1309/LMAAGVXK05LUWOQN ABSTRACT

More information

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O

More information

Epidemiology of HIV Among Women in Florida, Reported through 2014

Epidemiology of HIV Among Women in Florida, Reported through 2014 To protect, promote and improve the health of all people in Florida through integrated state, county, and community efforts. Created: 12/4/14 Revision: 1/27/15 Epidemiology of HIV Among Women in Florida,

More information